Process for increasing the antagonistic effect of peptidic compo

Details Process for increasing the antagonistic effect of peptidic compo Process for increasing the antagonistic effect of peptidic compo

1987-05-19

1989-05-30

Phillips, Delbert R.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514800, A61K 3743

Patent

active

048351393

ABSTRACT:
The antagonistic effect of the releasing hormone of LH and FSH or of one of its synthetic analogues selected from the group

REFERENCES:
patent: 3773919 (1970-10-01), Boswell et al.
patent: 3835108 (1972-02-01), Imner et al.
patent: 3887699 (1975-06-01), Yolles
patent: 4010125 (1975-06-01), Schally et al.
patent: 4018726 (1977-04-01), Schally et al.
patent: 4024121 (1977-05-01), Schally et al.
patent: 4234571 (1980-11-01), Nestor et al.
patent: 4585651 (1986-04-01), Beck et al.
patent: 4675189 (1987-06-01), Kent et al.
Chang, J. Biseng., vol. 1, pp. 25-32, 1976.
Clayton, J. Endoc. vol. 111, pp. 152-161, 1981.
Nestor, "Long Acting LHRH Agonists and Antagonists" (1984).
Sanders, "An Injectable Biodegradable Controlled Release Delivery System for Nafarelin Acetate" (1984).
J. Pharma. Sci., vol. 59, No. 10, p. 1373, Oct. 1970.
"Controlled Release of Biologically Active Agents", Tanquary A. C., Lacey R. E., editors, Plenum Press, New York, 1974.
"Polymeric Delivery Systems", Kostelnik R. J. ed., Midl. Macromol. Monogr., vol. 5, 1978.
"Sustained and Controlled Release Drug Delivery Systems", Robinson J. R. ed., Marcel Dekker, New York, 1979.
"Controlled Release of Bioactive Materials", Baker R. ed., Academic Press, New York, 1980.
"Controlled Release of Macromolecules", Chemtech, pp. 98-105, Feb. 1982.
European Patent Office's letter dated Oct. 24th, 1983, Ref. IMA/22210.
U.S. Patent 3,773,919, filed Oct. 8th, 1970, published Nov. 20th, 1973, (E. I. DuPont de Nemours, U.S.A.), G. A. Boswell and R. M. Scribner, Inventors.
"Biodegradable Semipermeable Microcapsules Containing Enzymes, Hormones, Vaccines, and other Biologicals", Thomas M. S. Chang--Journ. Bioengineering, vol. 1, pp. 25-32, 1976.
"Sustained Release Microcapsules and Microparticles of Polylactide Polymer", Yolles et al., J. Pharma. Sci., vol. 64, p. 348, 1975.
"New Long-Acting injectable Microcapsule Contraceptive System", Lee R. Beck et al., Am. J. Obstet. Gynecol., vol. 135, No. 3, pp. 419-426, Oct. 1979.
"A New Long-Acting Injectable Microcapsule System for the Administration of Progesterone", Lee R. Beck et al., Fertility and Sterility, vol. 31, No. 5, pp. 545-551, May 1979.
"Long-Acting Steroidal Contraceptive Systems", Lee R. Beck et al., Research Frontiers in Fertility Regulation, vol. 1, No. 1, Jul. 1980.
"Sustained Release of Antibiotics from Biodegradable Microcapsules", D. H. Lewis et al. (SRI), 7th International Symposium on Controlled Release of Bioactive Materials, Ft. Lauderdale, Fla., Jul. 28-30th, 1980.
"Lactic/Glycolic Acid Polymers", Donald L. Wise et al., Drug Carriers in Biology and Medicine, Gregory Gregoriadis ed., Academic Press-New York, pp. 237-270, 1979.
Applicants letter (Mewburn Ellis & Co., Authorized Representative), dated Apr. 27th, 1986.
U.S. Patent 4,010,125, filed Jun. 12th, 1975, published Mar. 1st, 1977.
U.S. Patent 3,835,108, filed on Feb. 15th, 1972, published Sep. 10th, 1974.
(a) "Microencapsulation of the Peptide Nafarelin Acetate for Controlled Release", John S. Kent et al., Long-Acting Contraceptive Delivery Systems, Zatuchni et al. ed., Harper & Row-Philadelphia, pp. 169-179, 1983.
(b) "Comparisons of the Potential Utility of LHRH Agonists and Antagonists for Fertility Control", Brian H. Vickery.
(c) "Controlled Delivery of an LHRH Analogue from Biodegradable Injectable Microspheres", Lynda M. Sanders et al., Journal of Controlled Release, vol. 2, pp. 187-195, 1985.
(d) "An injectable Biodegradable Controlled Release Delivery System For Nafarelin Acetate", L. M. Sanders et al., in LHRH and its analogues, Labrie, Belanger and Dupont Eds., pp. 53-62, 1984.
"Radioimmunoassay of (D-Trp6)-Luteinizing Hormone-Releasing Hormone: Its Application to Animal Pharmacokinetic Studies after Single Injection and Long-Acting Formulation Administration", Eric Ezan et al., Regulatory Peptides, vol. 14, pp. 155-167, 1986.
"Inhibition of Prostate Tumors by Agonistic and Antagonistic Analogs of LH-RH", A. V. Schally et al. The Prostate, vol. 4, pp. 545-552, 1983.
"Current Status of Antagonistic Analogs of LH-RH as a Contraceptive Method in the Female", A. V. Schally et al., Research Frontiers in Fertility Regulation, vol. 2, No. 5, Jul. 1983.
"Long-Acting Delivery Systems for Peptides: Inhibition of Rat Prostate Tumors by Controlled Release of (D-Trp6)-Luteinizing Hormone-Releasing Hormone from Injectable Microcapsules", A. V. Schally et al., Proc. Natl. Acad. Sci., vol. 81, pp. 5845-5848, Sep. 1984.
"Prolonged Controlled-Release of Nafarelin, a Luteinizing Hormone-Releasing Hormone Analogue, from Biodegradable Polymeric Implants: Influence of Composition and Molecular Weight of Polymer", L. M. Sanders et al., J. Pharm. Sci., vol. 75, No. 4, pp. 356-360, Apr. 1986.

Affiliated with

Also associated with

Rating

Process for increasing the antagonistic effect of peptidic compo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for increasing the antagonistic effect of peptidic compo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for increasing the antagonistic effect of peptidic compo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2152669